Dexmethylphenidate Hydrochloride Articles
Intellipharmaceutics and Par Pharma expand Focalin accord
19 August 2011
Vasogen and IntelliPharmaCeutics agree to merge
17 August 2009
Celgene swings back to profit in 1st qtr
5 May 2009
FDA approves 30-min onset for Novartis' Focalin XR
1 December 2008
Celgene's 3rd-qtr profit triples on drug sales
17 November 2008
Celgene profits double on rocketing sales
11 August 2008
Focalin XR manages ADHD better than Concerta ER
21 July 2008
Celgene posts 1st-qtr loss on Pharmion costs
19 May 2008
Celgene's
14 January 2008
FDA accepts ANDA for Par's generic Focalin
29 October 2007
Celegene's 2nd-qtr 2007 income soars 187.2%
6 August 2007
Celgene's 1st-qtr 2007 net income soars 61.4%
28 May 2007
Teva's generic Focalin cleared by US FDA
5 February 2007
Celgene's profits nosedive 82%
6 February 2006
Novartis sees strong performance with record results in 2005
30 January 2006
FDA action in brief
20 June 2005
FDA OKs Celgene and Novartis' ADHD drug
13 June 2005
Celgene posts record 1st-qtr EPS
9 May 2005
Novartis' Ritalin LA cleared in USA
17 June 2002
Novartis' Ritalin LA cleared in USA
17 June 2002
Showing 1-21 of 21 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
